AlloVir, Inc. (NASDAQ:ALVR) Short Interest Down 11.1% in October

AlloVir, Inc. (NASDAQ:ALVR) saw a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 4,890,000 shares, a decline of 11.1% from the September 30th total of 5,500,000 shares. Based on an average daily trading volume, of 151,000 shares, the short-interest ratio is currently 32.4 days.

Institutional Trading of AlloVir

Hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC boosted its holdings in shares of AlloVir by 152.3% in the second quarter. Cubist Systematic Strategies LLC now owns 49,816 shares of the company’s stock valued at $36,000 after buying an additional 30,072 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in AlloVir in the 2nd quarter valued at $55,000. Price T Rowe Associates Inc. MD boosted its stake in AlloVir by 127.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 97,986 shares of the company’s stock worth $74,000 after purchasing an additional 54,900 shares during the period. Marquette Asset Management LLC bought a new position in AlloVir during the 1st quarter worth about $135,000. Finally, Acadian Asset Management LLC increased its holdings in AlloVir by 694.6% during the 1st quarter. Acadian Asset Management LLC now owns 1,587,451 shares of the company’s stock worth $1,197,000 after purchasing an additional 1,387,666 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

AlloVir Stock Up 4.6 %

ALVR opened at $0.89 on Wednesday. The stock has a market cap of $103.08 million, a P/E ratio of -0.73 and a beta of 0.79. AlloVir has a 12 month low of $0.58 and a 12 month high of $2.49. The company has a fifty day simple moving average of $0.78 and a 200 day simple moving average of $0.77.

AlloVir (NASDAQ:ALVR) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. On average, equities research analysts expect that AlloVir will post -0.5 earnings per share for the current fiscal year.

About AlloVir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.